Qingqing Qiao

Jan 6, 2025 | onlinelibrary.wiley.com | Yinan Li |Xiu Huang |Qingqing Qiao |Yingying Li

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adma202414237-sup-0001-SuppMat.docx48.4 MB Supporting Information References 1, , , , , , , , , , , , , , , , , , , , , , , , Lancet. 2020, 395, 200. 2, , , Int. J. Mol. Sci. 2019, 20. 3, , , , Crit. Rev. Microbiol. 2013, 39, 229. 4, Nature. 2002, 420, 885. 5, , Immunity. 2014, 40, 463. 6, , , Cell. 2006, 124, 783. 7, , Curr. Opin. Immunol. 2008, 20, 420.

Aug 29, 2024 | onlinelibrary.wiley.com | Yinan Li |Xiu Huang |Yingying Li |Qingqing Qiao

1 Introduction Current drug therapies for tumors primarily rely on chemotherapy, targeted therapy, and immunotherapy. However, there is currently no research on the development of new therapies aimed at inducing tumor fibrosis by mimicking organ fibrosis. Fibrosis is characterized by the formation of a dense network of collagen fibers and represents a crucial mechanism of body tissue repair mode.[1] Current research suggests that tumor fibrosis plays a dual role in tumor growth and metastasis.